Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096515 | 0.89 | SLC2A1 (0.51) | DAORAB9ASLC2A1SLC11A2 | |
| SCHEMBL4480629 | 0.82 | DAO (0.44) | DAORAB9ASLC2A1FGFR2FGFR3 | |
| SCHEMBL13761994 | 0.82 | MAPT (0.43) | RAB9ASLC2A1MAPTCOMTTRPV1 | |
| SCHEMBL4468876 | 0.80 | PTGS2 (0.43) | DAORAB9AFGFR2FGFR3PTGS2 | |
| SCHEMBL9454944 | 0.79 | MAPT (0.53) | DAORAB9AMAPTCOMTSLC11A2 | |
| SCHEMBL4477952 | 0.77 | DAO (0.40) | DAOPTGS2 | |
| SCHEMBL4470825 | 0.76 | PTGES (0.44) | RAB9ASLC2A1MAPTCOMTTRPV1 | |
| SCHEMBL4486775 | 0.73 | SLC2A1 (0.46) | SLC2A1MAPTSLC11A2 | |
| SCHEMBL4484287 | 0.73 | DAO (0.49) | DAOMAPTGPR84 | |
| SCHEMBL9267476 | 0.73 | MAPT (0.46) | DAORAB9ASLC2A1MAPTCOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | G6PD, PNPO, PLPBP | DAO 2428/4885RAB9A 2000/4885SLC2A1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.